Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005079421> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2005079421 endingPage "300" @default.
- W2005079421 startingPage "298" @default.
- W2005079421 abstract "The Standard and New Antiepileptic Drug (SANAD) trial 1 Marson AG Al-Kharusi AM Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369: 1000-1015 Summary Full Text Full Text PDF PubMed Scopus (708) Google Scholar was a multicentre, randomised, open-label comparison of drug treatments for patients with newly diagnosed seizures of presumed partial onset, done in the UK from 2000 to 2006. The original report of arm A of the trial focused on differences in outcomes between five drugs; in this issue of The Lancet Neurology, Bonnett and colleagues 2 Bonnett L Tudur-Smith C Smith D Williamson P Chadwick D Marsden AG Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012; (published online Feb 28.)https://doi.org/10.1016/S1474-4422(12)70018-2 Summary Full Text Full Text PDF PubMed Scopus (49) Google Scholar report the results of subgroup analyses of data derived from SANAD arm A that focus on patient-related prognostic factors at the time of diagnosis. The investigators have gone beyond measurement of isolated factors and have identified an array of prognostic items, which together can form the elements of a predictive model. These data could be used in the future to assess an individual's likely therapeutic outcome, defined as time to treatment failure and probability of 12 months of remission from seizures. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trialWe present a thorough investigation of prognostic factors from a large randomised controlled trial in patients starting antiepileptic monotherapy. If validated, our models could aid in individual patient risk stratification and the design and analysis of epilepsy trials. Full-Text PDF Open Access" @default.
- W2005079421 created "2016-06-24" @default.
- W2005079421 creator A5015461885 @default.
- W2005079421 date "2012-04-01" @default.
- W2005079421 modified "2023-09-27" @default.
- W2005079421 title "What does the future hold for patients with epilepsy?" @default.
- W2005079421 cites W1984601418 @default.
- W2005079421 cites W1994572997 @default.
- W2005079421 cites W2044642402 @default.
- W2005079421 cites W2057810569 @default.
- W2005079421 cites W2081167060 @default.
- W2005079421 cites W2124847836 @default.
- W2005079421 cites W2129184868 @default.
- W2005079421 cites W2138521331 @default.
- W2005079421 doi "https://doi.org/10.1016/s1474-4422(12)70041-8" @default.
- W2005079421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22377179" @default.
- W2005079421 hasPublicationYear "2012" @default.
- W2005079421 type Work @default.
- W2005079421 sameAs 2005079421 @default.
- W2005079421 citedByCount "1" @default.
- W2005079421 countsByYear W20050794212019 @default.
- W2005079421 crossrefType "journal-article" @default.
- W2005079421 hasAuthorship W2005079421A5015461885 @default.
- W2005079421 hasConcept C118552586 @default.
- W2005079421 hasConcept C142724271 @default.
- W2005079421 hasConcept C16568411 @default.
- W2005079421 hasConcept C187212893 @default.
- W2005079421 hasConcept C204787440 @default.
- W2005079421 hasConcept C2776608144 @default.
- W2005079421 hasConcept C2777683783 @default.
- W2005079421 hasConcept C2778186239 @default.
- W2005079421 hasConcept C2778802184 @default.
- W2005079421 hasConcept C2779253243 @default.
- W2005079421 hasConcept C2781176495 @default.
- W2005079421 hasConcept C71924100 @default.
- W2005079421 hasConceptScore W2005079421C118552586 @default.
- W2005079421 hasConceptScore W2005079421C142724271 @default.
- W2005079421 hasConceptScore W2005079421C16568411 @default.
- W2005079421 hasConceptScore W2005079421C187212893 @default.
- W2005079421 hasConceptScore W2005079421C204787440 @default.
- W2005079421 hasConceptScore W2005079421C2776608144 @default.
- W2005079421 hasConceptScore W2005079421C2777683783 @default.
- W2005079421 hasConceptScore W2005079421C2778186239 @default.
- W2005079421 hasConceptScore W2005079421C2778802184 @default.
- W2005079421 hasConceptScore W2005079421C2779253243 @default.
- W2005079421 hasConceptScore W2005079421C2781176495 @default.
- W2005079421 hasConceptScore W2005079421C71924100 @default.
- W2005079421 hasFunder F4320307773 @default.
- W2005079421 hasFunder F4320307813 @default.
- W2005079421 hasFunder F4320308489 @default.
- W2005079421 hasFunder F4320322148 @default.
- W2005079421 hasFunder F4320327918 @default.
- W2005079421 hasIssue "4" @default.
- W2005079421 hasLocation W20050794211 @default.
- W2005079421 hasLocation W20050794212 @default.
- W2005079421 hasOpenAccess W2005079421 @default.
- W2005079421 hasPrimaryLocation W20050794211 @default.
- W2005079421 hasRelatedWork W1658899326 @default.
- W2005079421 hasRelatedWork W2067569181 @default.
- W2005079421 hasRelatedWork W2070762175 @default.
- W2005079421 hasRelatedWork W2080867598 @default.
- W2005079421 hasRelatedWork W2114708176 @default.
- W2005079421 hasRelatedWork W2138521331 @default.
- W2005079421 hasRelatedWork W2339822617 @default.
- W2005079421 hasRelatedWork W2507088515 @default.
- W2005079421 hasRelatedWork W4206742414 @default.
- W2005079421 hasRelatedWork W4283450076 @default.
- W2005079421 hasVolume "11" @default.
- W2005079421 isParatext "false" @default.
- W2005079421 isRetracted "false" @default.
- W2005079421 magId "2005079421" @default.
- W2005079421 workType "article" @default.